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ABSTRACT 
Resistance patterns against 24 antimicrobial agents were examined for 50 strains of methicillin-
resistant Staphylococcus aureus (MRSA) isolated at Hiroshima University Hospital during the 
period October 1990 and July 1991. Overall resistance (the percentage of highly and moderately 
resistant strains) to the antimicrobial agents is summarized as follows: methicillin 100%, flomoxef 
100% (,6-lactams); kanamycin 94%, tobramycin 94%, amikacin 100%, isepamicin 94%, gentami-
cin 80%, dibekacin 94%, arbekacin 2% (basic oligosaccharide group/aminocyclitols); ofloxacin 96%, 
temafloxacin 96%, levofloxacin 96% (fluoroquinolones); erythromycin 98%, clarithromycin 98%, 
josamycin 30% (macrolides); vancomycin 0% (glycopeptide); tetracycline 94%, minocycline 94% 
(tetracyclines); fosfomycin 100%; mikamycin B 30%, nosiheptide 0% (peptide); rifampicin 2% (an-
samycin); streptomycin 2% (basic oligosaccharide group); chloramphenicol 2%. 
Arbekacin resistance was observed in one case: the cross resistance was complete among the 
aminocyclitol antibiotics tested in this study and streptomycin, probably due to the ribosomal 
alteration. 
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this strain will be discussed. 
MATERIALS AND METHODS 
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Methicillin (DMPPC)-resistant Staphylococcus 
aureus (MRSA) was first reported in 19615). Since 
1980, MRSA has caused increasing problems in 
hospitals worldwide10'17•19). 
The low-affinity penicillin binding protein (PBP), 
designated PBP 2'21), PBP 2a4) or MRSA PBP15) 
encoded by DMPPC-resistance determinant mecA, 
a 2,130-bp segment of foreign DNA1), is responsi-
ble for the intrinsic resistance to ,6-lactams. 
Fifty MRSA strains were isolated at Hiroshima 
University Hospital between October 1990 and July 
1991. DMPPC-susceptible S. aureus FDA 209P was 
used as a reference. 
Furthermore, many MRSA strains are resistant 
to a variety of antibiotics including kanamycin 
(KM), tobramycin (TOB), gentamicin (GM), 
erythromycin (EM), clindamycin and tetracycline 
(TC)10). 
This study aimed to examine the incidence of 
multi-drug resistance in MRSA isolated at Hiroshi-
ma University Hospital during the period October 
1990 to July 1991. Although arbekacin (ABK) still 
remains to be one of the most effective antibiotics 
against the MRSA strains, a single strain isolated 
in April 1991 showed significant resistance to ABK. 
The circumstances surrounding the appearance of 
The antibiotics used and their manufacturers or 
distributors were as follows: DMPPC (SIGMA 
Chemical Co.); flomoxef (FMOX) and vancomycin 
(VCM) (Shionogi & Co., Ltd.); isepamicin (ISP) 
(Toyo Jozo Co., Ltd.); EM and clarithromycin 
(CAM) (Taisho Pharmaceutical Co., Ltd.); TC and 
minocycline (MINO) (Lederle Japan, Ltd.); fosfomy-
cin (FOM) (Meiji Seika Kaisha, Ltd.); nosiheptide 
(NH) (Mitsubishi Kasei Corporation); josamycin 
(JM), ofloxacin (OFLX) and levofloxacin (L VFX) 
(Daiichi Pharmaceutical Co., Ltd.); temafloxacin 
(TMFX) (Tanabe Seiyaku Co., Ltd.); mikamycin B 
(MKM-B) (Kanegafuchi Chemical Ind. Co., Ltd.); 
KM, TOB, dibekacin (DKB), amikacin (AMK), GM 
and ABK (Inst. Microb. Chem.); chloramphenicol 
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Table 1. Incidence of antibiotic resistance in the MRSA strains isolated at Hiroshima University Hospital from 
October 1990 to July 1991 (50 strains) 
Moderately 
Antimicrobial agent 
Resistant strains resistant strains Susceptible strains S. aureus 
No. of strains % No. of strains % No. of strains % FDA 209P 
(MIC, µg/ml) (MIC, µg/ml) (MIC, µg/ml) 
Methicillin (DMPPC) 45 (~ 100) 90 5 (12.5-25) 10 0 0 (0.10) 
Flomoxef (FMOX) 44 (~25) 88 6 (0.39-0.78) 12 0 0 (0.20) 
Kanamycin (KM) 47 (~50) 94 0 0 3 (0.78-3.13) 6 (0.78) 
Tobramycin (TOB) 47 (~25) 94 0 0 3 (0.20-0. 78) 6 (0.10) 
Dibekacin (DKB) 40 (~25) 80 7 (3.13-6.25) 14 3 (0.20-0. 78) 6 (0.20) 
Gentamicin (GM) 40 (~12.5) 80 0 0 10 (0.20-0.39) 20 (0.10) 
Amikacin (AMK) 47 (~6.25) 94 3 (1. 56-3.13) 6 0 0 (0.39) 
Isepamicin (ISP) 47 (~3.13) 94 3 (0.78-1.56) 6 (1.56) 
Arbekacin (ABK) 1 (> 100) 2 0 0 49 (0.20-1.56) 98 (0.20) 
Streptomycin (SM) 1 (> 100) 2 0 0 . 49 (0. 78-3.13) 98 (1.56) 
Erythromycin (EM) 49 (~12.5) 98 0 0 1 (0.39) 2 (0.20) 
Clarithromycin (CAM) 42 (~25) 84 7 (1.56-6.25) 14 1 (0.39) 2 (0.10) 
J osamycin (JM) 13 (~50) 26 2 (6.25-12.5) 4 35 (0.39-1.56) 70 (0.78) 
Tetracycline (TC) 47 (50-100) 94 0 0 3 (0.10-0.39) 6 (0.10) 
Minocycline (MINO) 47 (6.25-25) 94 0 0 3 (0.05-0.10) 6 (0.05) 
Fosfomycin (FOM) 48 (~50) 96 2 (12.5-25) 4 0 0 (0.78) 
Vancomycin (VCM) 0 0 0 0 50 (0.39-1.56) 100 (0.39) 
Ofloxacin (OFLX) 46 (6.25-25) 92 2 (0.78-3.13) 4 2 (0.39) 4 (0.10) 
Levofloxacin (L VFX) 46 (3.13-12.5) 92 2 (0.78) 4 2 (0.20-0.39) 4 (0.10) 
Temafloxacin (TMFX) 46 (6.25-12.5) 92 2 (0.78) 4 2 (0.10-0.20) 4 (0.05) 
Mikamycin B (MKM-B) 9 (~100) 18 6 (12.5-50) 12 35 (3.13-6.25) 70 (3.13) 
N osiheptide (NH) 0 0 0 
Rifampicin (RFP) 1 (1.56) 2 0 
Chloramphenicol (CP) 1 (100) 2 0 
(CP) (Wako Pure Chemical Ind., Ltd.); rifampicin 
(RFP) (Kanto Chemical Co., Inc.); streptomycin 
(SM) (Irvin Scientific). 
The minimum inhibitory concentration (MIC) was 
measured by two-fold agar dilution method with 
Mueller-Hinton agar (DIFCO Laboratories). Test 
strains grown overnight at 37°C in 5 ml of Meuller-
Hinton broth (MHB) (DIFCO Laboratories) were 
102-fold diluted with fresh MHB, and about 5 x 103 
CFU was applied with multipoint plating appara-
tus on the surface of agar plates. The plates were 
incubated at 37°C for 20 hr. 
The production of {3-lactamase by individual 
MRSA strains was monitored by using BBL 
cefinase (Becton Dickinson Microbiology Systems). 
The production of toxic shock syndrome toxin I 
(TSST-1) was monitored by the polymerase chain 
reaction using synthetic primers. The details will 
be reported elsewhere. 
RESULTS 
Fifty MRSA strains were classified as: resistant, 
moderately resistant or susceptible to each an-
0 50 (0.003-0.012)100 (0.003) 
0 49 (0.024-0.20) 98 (0.10) 
0 49 (1.56-6.25) 98 (3.13) 
timicrobial agent depending on their MICs accord-
ing to the definitions of Maple et al1°) and the 
British Society for Antimicrobial Chemotherapy2>. 
Resistance patterns of all the MRSA strains against 
24 antimicrobial agents as well as the MIC distri-
bution of individual compounds are shown in Ta-
bles 1 and 2, respectively. Many of the MRSA 
strains showed resistance to more than 15 antibi-
otics. The antibiotics, to which more than 90% 
strains were resistant, included: DMPPC, FMOX, 
KM, TOB, DKB, AMK, ISP, EM, CAM, TC, 
MINO, FOM, OFLX, LVFX and TMFX. The 
resistance against GM was slight lower (80%) than 
these antibiotics and 30% strains were resistant to 
JM and MKM-B. Forty-nine of 50 strains were sus-
ceptible to the antimicrobial activity of ABK, RFP, 
CP or SM (resistance, 2%) and no resistance was 
observed to VCM and NH. 
The resistance of MRSA to aminocyclitol antibi-
otics was determined by three inactivating enzymes: 
bifunctional 6 '-acetyltransferase/2' '-phosphotrans-
ferase AAC(6')/ APH(2"), 4' -adenyltransferase 
AAD(4') and 3'-phosphotransferase APH(3')20>. The 
Antibiotic Resistance in MRSA 81 
Table 2. MICs of 24 antibiotics against the MRSA strains isolated at Hiroshima University Hospital (50 strains) 
Antimicrobial agent 
MIC (µg/ml) 
Range 50% 90% FDA 209P 
DMPPC 12.5 - >100 >100 >100 0.10 
FMOX 0.39 - >100 50 100 0.10 
KM 0.78 - > 100 >100 >100 0.78 
TOB 0.20 - >100 50 100 0.10 
DKB 0.20 - >100 25 50 0.20 
AMK 1.56 - > 100 6.25 12.5 0.39 
GM 0.20 - >100 50 50 0.10 
ISP 0.78 - > 100 12.5 25 0.39 
ABK 0.20 - >100 0.78 0.78 0.20 
SM 0.78 - > 100 3.13 3.13 1.56 
EM 0.39 - >100 >100 >100 0.20 
CAM 0.39 - >100 100 >100 0.10 
JM 0.39 - >100 1.56 >100 0.78 
TC 0.10 - 100 100 100 0.10 
MINO 0.05 - 25 12.5 12.5 0.05 
FOM 12.5 - >100 >100 >100 0.78 
VCM 0.39 - 1.56 0.78 1.56 0.39 
OFLX 0.39 - 25 12.5 12.5 0.10 
LVFX 0.20 - 12.5 6.25 6.25 0.10 
TMFX 0.10 - 12.5 6.25 12.5 0.05 
MKM-B 3.13 - >100 6.25 >100 3.13 
NH 0.003 - 0.012 0.006 0.012 0.003 
RFP 0.024 - 1.56 0.05 0.1 0.1 
CP 1.56 - 100 3.13 6.25 3.13 
Table 3. Distribution of aminocyclitol aminoglycoside inactivating enzymes in the MRSA strains 
Phenotype 
KM8TOB8GM8 AMK8 ABK8SM8 
KMrTOB8GM8 AMK8 ABK8SM8 
KMrToBrGM8 AMKr ABK8SM8 





AAC (6')/APH (2") or 
AAC (6')/ APH (2") + APH (3') 
AAC (6')/APH (2")+AAD (4') or 
AAC (6')/APH (2")+AAD (4')+APH (3') 
not classified 
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When MLS-resistance is inducible, the strains are resistant to 14-membered macrolides (e.g., EM, CAM), but suscep-
tible to 16-membered maclorides (e.g., JM), lincosamides and streptogramin B-type antibiotics (e.g., MKM-B). 
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Fig. 1. Cumulative susceptibility of the MRSA strains 
to aminoglycoside-group antibiotics 
The MICs of S. aureus FDA 209P were as follows 
(µg/ml): KM, 0.78; TOB, 0.10; DKB, 0.20; GM, 0.10; 
AMK, 0.39; ISP, 1.56; ABK, 0.78; SM, 1.56. 
divergent phenotypes with respect to the resistance 
patterns to KM, TOB, GM and AMK were account-
ed for by the expression of these inactivating en-
zymes in individual MRSA strains: 
KM8TOB8GM8AMK8 , no enzyme; KMrTOB8GMs 
AMKs, APH(3'); KMrTOBrGM8AMKr(so-called TOBr 
type), AAD(4'); KMrTOBrGMrAMKs (so-called GMr 
type), AAC(6')/APH(2") or AAC(6')/APH(2") + 
APH(3'); KMrTOBrGMrAMKr (so-called Mixr type), 
AAC(6')/APH(2") + AAD(4') or AAC(6')/APH(2") 
+ AAD(4') + APH(3'). As can be seen in Table 3, 
45 strains expressed AAD(4') alone (7 strains) or 
in combination with AAC(6')/APH(2") (38 strains), 
three strains were not protected by any inactivat-
ing enzymes, one strain expressed APH(3') and one 
strain was ABK resistant. The resistance pattern 
of the ABKr strain could not be explained by 
these inactivating enzymes. The MIC distribution 
of each aminocyclitol antibiotic or SM is shown in 
Fig. 1. 
The MLS resistance was inducible in 34 strains 
with a EMrCAMrJM8MKM-B8 drug-resistance 
phenotype and constitutive in 15 strains with a 
>100 
100 
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Fig. 2. Relationship between resistance to TC and 
MINO of the MRSA strains isolated at Hiroshima 
University Hospital 
Figures represent the number of MRSA strains with 
the corresponding MICs. The MICs of TC and MINO 
for the ABKr strain are 50 and 12.5 µg/ml, respec-
tively, whereas those for the coagulase type IV strain 
are 0.1 and 0.05 µg/ml, respectively. 
* represents the MICs of TC and MINO for S. aureus 
FDA 209P. 
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Fig. 3. Relationship between resistance to TC and 
L VFX of the MRSA strains isolated at Hiroshima 
University Hospital 
Figures represent the number of MRSA strains with 
the corresponding MICs. 
* represents the MI Cs of TC and L VFX for S. aureus 
FDA 209P. a, ABKr strain; b, coagulase type IV 
strain. 
EMrCAMrJMrMKM-Br phenotype (Table 4). Only 
one strain was susceptible to any antibiotics in the 
MLS group. 
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As for tetracyclines and fluoroquinolones, the 
resistance was not expressed independently. The 
correlation between the resistances to TC and 
MINO and that between TC and L VFX is shown 
in Figs. 2 and 3, respectively. 
DISCUSSION 
In a previous study covering the period 1984 to 
September 199016), there was reported a vital 
turning point with respect to the drug-resistance 
of MRSA strains isolated at Hiroshima University 
Hospital. MRSA strains isolated before and after 
this turning point were tentatively designated 
groups A and B, respectively. MRSA strains iso-
lated during the period covered in the present 
study, i.e., from October 1990 to July 1991, were, 
therefore, classified as group C. The number of 
strains were 22 (group A), 12 (group B) and 50 
(group C). 
MRSA strains harbor mecA gene coding for low-
affinity PBP responsible for their intrinsic 
resistance to {j-lactams, whereas the {j-lactamase is 
thought to contribute to borderline resistance to {j-
lactams. The coagulase types and productivities of 
TSST-1 were characterized for 50 MRSA strains in 
group C. As for the coagulase type, type II strains 
amount to 49 with one type IV strain. TSST-1 was 
produced by all the type II strains but not by the 
type IV strain. Nakayama et al12) reported an in-
verse correlation between the productivities of 
TSST-1 and {1-lactamase, a fact confirmed in this 
study. The frequencies of {1-lactamase-positive 
strains in groups A, Band C were 64% (14 of 22), 
8% (1 of 12) and 2% (1 of 50), respectively. The 
aforementioned turning point defined by the drug 
resistance was also concerned with the production 
of {j-lactamase or TSST-1. 
The resistance pattern of MRSA strains to 
aminocyclitol antibiotics can be conveniently ac-
counted for by the function of three different in-
activating enzymes, AAD(4'), APH(3') and 
AAC(6')/APH(2") (Table 3) encoded by aadD, aphA 
and aacA-aphD, respectively. Two types of MRSA 
strains were recognized by Ubukata et al differing 
in the length of HindIII fragments carrying mecA 
gene: 4.3- and 4.0-kb fragments23). The HindIII 
fragment of TOE-resistant (TOBr) type MRSA 
strains containing both mecA and aadD genes was 
confined to the longer 4.3-kb fragment23) and this 
type of MRSA had rapidly become dominant in 
Japan since its first report in 19837). The linkage 
between mecA and aadD in the MRSA strains in 
group C was as high as 92% ( 45 of 49). 
AAC(6')/APH(2") is also frequently detected in 
MRSA strains either alone (GM-resistant type, 
GMr type) or together with APH(3') and/or 
AAD( 4'). The incidence of coexpression of 
AAC(6')/APH(2") and AAD(4') (Mix-resistant type, 
Mixr type) has been extremely high since April 
199016). In this study, the numbers of TOBr-type 
MRSA and Mixr-type MRSA strains were 7 and 
38, respectively (45 altogether) with one GMr-type 
strain, three inactivating enzyme-free strains includ-
ing the coagulase type IV strain, and one ABKr 
strain (Table 3). Most of them ( 45 of 50) were high-
ly resistant to DMPPC (MICs, ~ 100 µg/ml). The 
five strains consisting of the GMr-type strain, 
three aminocyclitol-susceptible strains and one 
Mixr-type strain showed low level resistance to 
DMPPC (MICs, 6.25 - 50 µg/ml). 
An ABKr strain was isolated, for the first time, 
with the MIC of ABK higher than 100 µg/ml; in 
contrast, the reported MICs of ABK for ABKr 
strains ranged from 6.25 to 50 µg/ml 11). Further-
more, the ABKr strain was resistant to all the 
aminocyclitol antibiotics tested as well as SM 
(MICs, > 100 µg/ml; Fig.1), implying that the 
resistance resulted from the ribosomal alteration. 
The drug-resistance properties of the ABKr strain 
were not only unique among the MRSA strains but 
also far different from those of another MRSA 
strain isolated from the same patient. Properties 
of the ABKr strain included the following: resis-
tant to tetracyclines such as TC and MINO but 
rather susceptible to fluoroquinolones (Fig. 3), and 
exceptionally resistant to RFP. Taking these results 
into consideration, a small population of ABKr 
strains might have existed before ABK was clini-
cally used and the ABKr strain was isolated by 
chance in the presence of ABK. 
The coagulase type IV strain was susceptible to 
all the antibiotics tested except for DMPPC and 
FOM. On the other hand, no resistance was ob-
served against VCM and NH. The efficacy of CP 
and RFP was satisfactory (resistance, 2% ); RFP 
resistance was only encountered with the ABKr 
strain. 
There are two well-characterized mechanisms of 
MRSA resistance to typical tetracyclines such as 
TC and MINO, one of which involves the efflux of 
antibiotics from bacteria (e.g., plasmid-encoded Tet 
K determinant) and the other involving ribosomal 
protection (e.g., chromosomal Tet M deter-
minant)9·14). The Tet K determinant mediated high-
level resistance to TC but not to MINO. In con-
trast, the Tet M determinant expressed resistance 
to TC and MINO. In 47 of 50 MRSA strains, the 
resistance to tetracyclines seemed accounted for by 
the Tet M determinant, since they showed a 
TCrMINOr phenotype (Fig. 2). The remaining 3 
strains were susceptible to tetracyclines with a 
TCsMINOs phenotype. 
The incidence of tetracycline and fluoroquinolone 
resistance increased simultaneously since April 
199016). Moreover, these two types of drug 
resistance were coexpressed as seen in Fig. 3 
(phenotype, TCrL VFXr). Only one exception to this 
general rule was the ABKr strain (TCrL VFX8). 
The resistance to a number of structurally unrelat-
ed drugs was often conferred by efflux transport-
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ers such as Bacillus subtilis Bmr13), Tet K in S. 
aureus14), Tet A, B and C in gram-negative 
bacteria9) and Nor A responsible for fluoroquinolone 
resistance in MRSA 6•22). Based on these findings, 
the authors propose the existence of common ef-
flux protein for TC, MINO and LVFX, which can 
be distinguished from Tet K and Nor A. 
Macrolide-lincosamide-streptogramin B (MLS) 
resistance was first described in S. aureus3) and is 
now common in this and other species of 
staphylococci. MKM-B is structurally related to 
streptogramin B and is included in this group of 
antibiotics. The MLS resistance is conferred by the 
function of methylase which converts an adenosine 
residue of 238 ribosomal RNA to 6-N-
dimethyladenosine, thereby reducing the affinity of 
the ribosome for all the MLS-group antibiotics8). 
The classical MLS resistance is inducible. When ex-
pression is inducible, MRSA is resistant to 
14-membered and 15-membered macrolides only 
with a EMrCAMrJM8MKM-B8 phenotype. In con-
trast, constitutive MLS-resistance gives a 
EMrCAMrJMrMKM-Br phenotype. Tillotson et al18) 
suggested that the acquision of TC resistance 
resulted in a phenotypical change from constitutive 
MLS resistance to inducible one. In agreement with 
those findings, the TC resistant MRSA strains in 
groups A and B exhibited inducible MLS resistance 
and the marked phenotypical change in MLS 
resistance was observed between March and April 
1990 from constitutive type to inducible one (in 
other words, from Tes to TCr). MRSA strains 
with a TCrEMrCAMr JM8MKM-B8 phenotype were 
often isolated until March 1991. Since April 1991 
constitutive MLS resistance has become dominant 
again without losing TC resistance (phenotype, 
TCrEMrCAMrJMrMKM-Br). 
Because of the isolation of ABKr strain and a 
progressive increase in the number of antibiotics to 
which MRSA clinical isolates are resistant, the con-
tinued surveillance for the drug resistance seems 
important. 
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